South African Double Olympic 800 metres champion Caster Semenya has expressed her dissatisfaction after losing her appeal to the Swiss Federal Tribunal to set aside a 2019 Court of Arbitration (CAS) ruling that female athletes with a high natural level of testosterone must take medication to reduce it.
Chills my people,A man can change the rules but the very same man can not rule my life,What I'm saying is that I might have failed against them the truth is that I have won this battle long ago,Go back to my achievements then you will understand.Doors might be closed not locked.
— Caster Semenya (@MightyCaster) September 8, 2020
In May last year, the South African sprinter approached the tribunal after CAS, sport’s highest court, ruled that World Athletics regulations were necessary for athletes with differences in sexual development (DSDs) in races ranging from 400 metres to a mile, to ensure fair competition.
The tribunal found the requirement of subjecting certain female athletes to drug or surgical interventions as a precondition to compete does not amount to a violation of Swiss public policy, Semenya’s lawyers said in a statement on Tuesday.
Testosterone increases muscle mass, strength and haemoglobin, which affects endurance.
Some competitors have said women with higher levels of the hormone have an unfair advantage.
“I am very disappointed by this ruling, but refuse to let World Athletics drug me or stop me from being who I am. Excluding female athletes or endangering our health solely because of our natural abilities puts World Athletics on the wrong side of history. I will continue to fight for the human rights of female athletes, both on the track and off the track, until we can all run free the way we were born. I know what is right and will do all I can to protect basic human rights, for young girls everywhere.”
Semenya has already indicated that she would focus on the shorter 200-metres sprint event, which falls outside of the regulations.
Tokyo Olympic Games were postponed to next year due to the COVID-19 pandemic.
